Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Photoreceptors and Visual Pathways

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From Wonder to Anger: <i>Rethinking</i> The Showman and the Slave <i>Through Standpoint Theory</i>.

Perspectives in biology and medicine·2024

Same author

Understanding the role of structural racism in sleep disparities: a call to action and methodological considerations.

Sleep·2022

Same author

Sleeping while disabled, disabled while sleeping.

Sleep health·2017

Same author

Antibiotic Prophylaxis in Orbital Fractures.

The open ophthalmology journal·2017

Same author

Transient vision loss after ocriplasmin injection.

Retina (Philadelphia, Pa.)·2015

Same author

Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device.

Retina (Philadelphia, Pa.)·2010

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Acute vision loss after ocriplasmin use.

Benjamin Reiss¹, Lindsay Smithen, Sam Mansour

¹Department of Ophthalmology, The George Washington University, Washington, D.C.

Retinal Cases & Brief Reports

|March 6, 2015

Summary

Ocriplasmin injection can cause vision loss, potentially linked to increased foveal schisis and subretinal cavities, not just ellipsoid layer disruption. This case highlights a prolonged dysfunction after the treatment.

More Related Videos

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

Published on: April 21, 2022

Related Experiment Videos

Last Updated: Apr 16, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

In Vivo Vascular Injury Readouts in Mouse Retina to Promote Reproducibility

Published on: April 21, 2022

Area of Science:

Ophthalmology
Retinal Imaging
Pharmacological Interventions

Background:

Reports indicate transient vision loss and ellipsoid layer disruption post-ocriplasmin injection.
Spectral domain optical coherence tomography (SD-OCT) is crucial for visualizing retinal changes.

Observation:

A 55-year-old woman with vitreomacular traction and foveal schisis received ocriplasmin.
She experienced sudden, transient vision loss post-injection.
SD-OCT revealed increased schisis, a new subretinal cavity, and persistent ellipsoid layer dysfunction at 9 months.

Findings:

The patient's vision loss correlated with increased foveal schisis and a new subretinal cavity.
Ellipsoid layer disruption was observed but showed limited correlation with visual function in this case.
This suggests alternative mechanisms for vision loss beyond primary ellipsoid layer damage.

Implications:

This case expands understanding of ocriplasmin's potential ocular side effects.
It emphasizes the need for comprehensive imaging and functional assessment post-treatment.
Further research is warranted to elucidate the precise mechanisms of vision dysfunction after ocriplasmin.